PREOTACT APPROVED IN EUROPE

NPS Pharmaceuticals and its partner Nycomed have received market authorization from the European Medicines Evaluation Agency (EMEA) for Preotact (parathyroid hormone [rDNA origin] for injection).

Preotact is approved to treat postmenopausal women at risk of bone fractures from osteoporosis. The company plans to begin shipping the drug later this year.